Skip to main content

Advertisement

SpringerLink
Log in

Atopic Keratoconjunctivitis: Diagnosis and Treatment

  • Cornea (K Houser, Section Editor)
  • Published:
Current Ophthalmology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review aims to provide an update on the diagnosis and the latest management options for atopic keratoconjunctivitis (AKC).

Recent Findings

Atopic keratoconjunctivitis (AKC) is a chronic, inflammatory condition seen in patients with atopic dermatitis at any point during the disease course. It is the most severe type of allergic eye disease and can have potentially severe ocular sequelae leading to blindness. Recent additions to the armamentarium for the treatment of severe atopic disease have focused on steroid sparing agents that include systemic T cell and calcineurin inhibitor medications as well as novel drug delivery systems.

Summary

Ocular involvement in atopic disease includes the periorbita and eyelids, conjunctiva, and cornea. Progressive disease can lead to blindness, especially in younger patients with more severe disease. Effective management of this condition requires a multidisciplinary approach, including dermatology, allergy and immunology, and ophthalmology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hogan MJ. Atopic keratoconjunctivitis. Trans Am Ophthalmol Soc. 1952;50:265–81.

    CAS  Google Scholar 

  2. Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478–85.

    Article  CAS  Google Scholar 

  3. Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7(5):442–5.

    Article  Google Scholar 

  4. •• Leonardi A, Modugno RL, Salami E. Allergy and dry eye disease. Ocular Immunology and Inflammation. 2021;29(6):1168–76. Discusses the overlap and key features between ocular allergy and dry eye disease.

  5. Darlenski R, Kazandjieva J, Hristakieva E, Fluhr JW. Atopic dermatitis as a systemic disease. Clin Dermatol. 2014;32(3):409–13.

    Article  Google Scholar 

  6. •• Hossain IT, Sanghi P, Manzouri B. Pharmacotherapeutic management of atopic keratoconjunctivitis. Expert Opinion on Pharmacotherapy. 2020;21(14):1761–9. Excellent in-depth review of atopic keratoconjunctivitis, its pathogenesis, and current treatment modalities.

  7. Enríquez-de-Salamanca A, Calder V, Gao J, Galatowicz G, García-Vázquez C, Fernández I, et al. Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation. Cytokine. 2008;44(1):160–7.

    Article  Google Scholar 

  8. Metz DP, Hingorani M, Calder VL, Buckley RJ, Lightman SL. T-cell cytokines in chronic allergic eye disease. J Allergy Clin Immunol. 1997;100(6):817–24.

    Article  CAS  Google Scholar 

  9. Roy N, Levanon S, Asbell PA. Potential biomarkers for allergic conjunctival diseases. Eye Contact Lens. 2020;46 Suppl 2(Suppl 2):S109-s21.

  10. Galicia-Carreón J, Santacruz C, Hong E, Jiménez-Martínez MC. The ocular surface: from physiology to the ocular allergic diseases. Rev Alerg Mex. 2013;60(4):172–83.

    Google Scholar 

  11. Matsuda A, Okayama Y, Ebihara N, Yokoi N, Hamuro J, Walls AF, et al. Hyperexpression of the high-affinity IgE receptor-beta chain in chronic allergic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2009;50(6):2871–7.

    Article  Google Scholar 

  12. Irkec MT, Bozkurt B. Molecular immunology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2012;12(5):534–9.

    Article  CAS  Google Scholar 

  13. Tuft SJ, Gregory WM, Buckley RJ. Acute corneal hydrops in keratoconus. Ophthalmology. 1994;101(10):1738–44.

    Article  CAS  Google Scholar 

  14. Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am. 2005;18(4):485–v.

    Google Scholar 

  15. Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol. 2008;9(4):233–44.

    Article  Google Scholar 

  16. Li J, Zhang L, Chen X, Chen D, Hua X, Bian F, et al. Pollen/TLR4 Innate Immunity Signaling Initiates IL-33/ST2/Th2 Pathways in Allergic Inflammation. Sci Rep. 2016;6:36150.

    Article  CAS  Google Scholar 

  17. Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int. 2012;61(1):3–17.

    Article  CAS  Google Scholar 

  18. Avunduk AM, Avunduk MC, Dayanir V, Tekelioglu Y. Further studies on the immunopathology of atopic keratoconjunctivitis using flow cytometry. Exp Eye Res. 1997;65(6):803–8.

    Article  CAS  Google Scholar 

  19. Chen X, Deng R, Chi W, Hua X, Lu F, Bian F, et al. IL-27 signaling deficiency develops Th17-enhanced Th2-dominant inflammation in murine allergic conjunctivitis model. Allergy. 2019;74(5):910–21.

    Article  CAS  Google Scholar 

  20. Li XM, Chen X, Gu W, Guo YJ, Cheng Y, Peng J, et al. Impaired TNF/TNFR2 signaling enhances Th2 and Th17 polarization and aggravates allergic airway inflammation. Am J Physiol Lung Cell Mol Physiol. 2017;313(3):L592-l601.

    Article  Google Scholar 

  21. Hu Y, Matsumoto Y, Adan ES, Dogru M, Fukagawa K, Tsubota K, et al. Corneal in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis. Ophthalmology. 2008;115(11):2004–12.

    Article  Google Scholar 

  22. Shoji J. Ocular allergy test and biomarkers on the ocular surface: clinical test for evaluating the ocular surface condition in allergic conjunctival diseases. Allergol Int. 2020;69(4):496–504.

    Article  CAS  Google Scholar 

  23. Calder V, Jolly G, Hingorani M, Adamson P, Leonardi A, Secchi A, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 1999;29(9):1214–22.

    Article  CAS  Google Scholar 

  24. Shiraki Y, Shoji J, Inada N, Tomioka A, Yamagami S. IL-1α antibody inhibits dose-dependent exacerbation of eosinophilic inflammation by crude house-dust-mite antigen in the conjunctiva of an atopic keratoconjunctivitis mouse model. Curr Eye Res. 2021;46(8):1115–24.

    Article  CAS  Google Scholar 

  25. Ueta M, Nishigaki H, Komai S, Sotozono C, Kinoshita S. Difference in the plasma level of miR-628-3p in atopic dermatitis patients with/without atopic keratoconjunctivitis. Immun, Inflamm Dis. 2021;9(4):1815–9.

    Article  CAS  Google Scholar 

  26. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One. 2012;7(7):e39803.

    Article  CAS  Google Scholar 

  27. Pietruszyńska M, Zawadzka-Krajewska A, Duda P, Rogowska M, Grabska-Liberek I, Kulus M. Ophthalmic manifestations of atopic dermatitis. Adv Dermatol Allergol/Postępy Dermatologii i Alergologii. 2020;37(2):174–9.

    Article  Google Scholar 

  28. Dogru M, Nakagawa N, Tetsumoto K, Katakami C, Yamamoto M. Ocular surface disease in atopic dermatitis. Jpn J Ophthalmol. 1999;43(1):53–7.

    Article  CAS  Google Scholar 

  29. Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology. 1998;105(4):637–42.

    Article  CAS  Google Scholar 

  30. • Sheng GT, Rizal AJ, MOphthal NLBS. Ocular co-morbidities in patients with atopic dermatitis-a cross-sectional study from a tertiary referral hospital, Malaysia. Med J Malaysia. 2022;77(1):7.Cross-sectional study on the ocular manifestations of patients with atopic dermatitis.

  31. Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin. 2010;30(3):323–36.

    Google Scholar 

  32. Brémond-Gignac D, Nischal KK, Mortemousque B, Gajdosova E, Granet DB, Chiambaretta F. Atopic keratoconjunctivitis in children: clinical features and diagnosis. Ophthalmology. 2016;123(2):435–7.

    Article  Google Scholar 

  33. • Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W. Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases. American journal of clinical dermatology. 2019;20(6):797–805. Comprehensive review of the pathogensis and treatment of ocular comorbidities of atopic dermatitis from a dermatologic perspective.

  34. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990;97(8):992–1000.

    Article  CAS  Google Scholar 

  35. Hsu JI, Pflugfelder SC, Kim SJ. Ocular complications of atopic dermatitis. Cutis. 2019;104(3):189–93.

    Google Scholar 

  36. Weng S-F, Jan R-L, Wang J-J, Tseng S-H, Chang Y-S. Association between atopic keratoconjunctivitis and the risk of keratoconus. Acta Ophthalmol. 2021;99(1):e54–61.

    Article  CAS  Google Scholar 

  37. •• Mocanu M, Vâță D, Alexa A-I, Trandafir L, Patrașcu A-I, Hâncu MF, et al. Atopic Dermatitis—Beyond the Skin. Diagnostics. 2021;11(9):1553. Dermatology and ophthalmology collaboration on the extra-cutaneous manifestations of atopic dermatitis.

  38. Khan M, Kundi N, Saeed N, Gulab A, Nazeer A. Incidence of keratoconus in spring catarrh. Br J Ophthalmol. 1988;72(1):41–3.

    Article  CAS  Google Scholar 

  39. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;106(6):1019–32.

    Article  CAS  Google Scholar 

  40. Ruiz-Lozano RE, Hernandez-Camarena JC, Roman-Zamudio M, Alcazar-Felix RJ, Davila-Cavazos O, Cardenas-de la Garza JA. Three types of cataract associated with atopic dermatitis and chronic topical corticosteroid use: A case report. Dermatol Ther. 2021;34(1):e14600.

  41. Easty D, Entwistle C, Funk A, Witcher J. Herpes simplex keratitis and keratoconus in the atopic patient. A clinical and immunological study. Trans Ophthalmol Soc U K. 1975;95(2):267–76.

    CAS  Google Scholar 

  42. Guzik T, Bzowska M, Kasprowicz A, Czerniawska-Mysik G, Wójcik K, Szmyd D, et al. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clin Exp Allergy. 2005;35(4):448–55.

    Article  CAS  Google Scholar 

  43. Hur MS, Lee JS, Jang M, Shin HJ, Lee YW. Analysis of the conjunctival microbiome in patients with atopic keratoconjunctivitis and healthy individuals. Ann Dermatol. 2021;33(2):163–9.

    Article  Google Scholar 

  44. Jan RL, Weng SF, Wang JJ, Tseng SH, Chang YS. Association between atopic keratoconjunctivitis and the risk of recurrent corneal erosion. Front Med (Lausanne). 2021;8:688355.

    Article  Google Scholar 

  45. Sasoh M, Mizutani H, Matsubara H, Furuta M, Matsui Y, Yamanaka K, et al. Incidence of retinal detachment associated with atopic dermatitis in Japan: review of cases from 1992 to 2011. Clin Ophthalmol. 2015;9:1129–34.

    Article  Google Scholar 

  46. Kothari N, Young RC, Read SP, Tutiven J, Perez VL, Flynn HW Jr, et al. Retinal detachment associated with atopic dermatitis. Ophthalmic Surg Lasers Imaging Retina. 2017;48(6):513–7.

    Article  Google Scholar 

  47. Hida T, Tano Y, Okinami S, Ogino N, Inoue M. Multicenter retrospective study of retinal detachment associated with atopic dermatitis. Jpn J Ophthalmol. 2000;44(4):407–18.

    Article  CAS  Google Scholar 

  48. Sy H, Bielory L. Atopic keratoconjunctivitis. Allergy Asthma Proc. 2013;34(1):33–41.

    Article  CAS  Google Scholar 

  49. • Yamamoto K, Wakabayashi Y, Kawakami S, Numata T, Ito T, Okubo Y, et al. Recent trends of ocular complications in patients with atopic dermatitis. Japanese Journal of Ophthalmology. 2019;63(5):410–6. Comparative cross-sectional study on the ocular manifestations of patients with atopic dermatitis.

  50. Orihara T, Hirota K, Yokota R, Kunita D, Itoh Y, Rii T, et al. Comparison of retinal detachment associated with atopic dermatitis with that of a blunt trauma. Nippon Ganka Gakkai Zasshi. 2015;119(7):457–63.

    Google Scholar 

  51. Uchio E, Kimura R, Migita H, Kozawa M, Kadonosono K. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):291–6.

    Article  Google Scholar 

  52. Al-Yaqout F, Feteih A. Ocular allergy. The Manual of Allergy and Clinical Immunology: CRC Press; 2022. p. 23–30.

    Google Scholar 

  53. Miyazaki D, Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, et al. Japanese guidelines for allergic conjunctival diseases 2020. Allergol Int. 2020;69(3):346–55.

    Article  CAS  Google Scholar 

  54. Jay JL. Clinical features and diagnosis of adult atopic keratoconjunctivitis and the effect of treatment with sodium cromoglycate. Br J Ophthalmol. 1981;65(5):335–40.

    Article  CAS  Google Scholar 

  55. Johnson HG, White GJ. Development of new antiallergic drugs (cromolyn sodium, lodoxamide tromethamine). What is the role of cholinergic stimulation in the biphasic dose response? Monogr Allergy. 1979;14:299–306.

  56. •• Bielory L, Schoenberg D. Emerging therapeutics for ocular surface disease. Current allergy and asthma reports. 2019;19(3):1–10.Comprehensive catalog of therapies for allergic conjunctivitis, vernal keratoconjunctivitis and atopic keratoconjuncvititis.

  57. Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol. 1999;117(5):643–7.

    Article  CAS  Google Scholar 

  58. Anzaar F, Gallagher MJ, Bhat P, Arif M, Farooqui S, Foster CS. Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea. 2008;27(8):884–8.

    Article  Google Scholar 

  59. Hingorani M, Moodaley L, Calder VL, Buckley RJ, Lightman S. A randomized, placebo-controlled trial of topical cyclosporin a in steroid-dependent atopic keratoconjunctivitis11Performed at Moorfields Eye Hospital, City Road, London EC1V 2PD. U K Commer Interes: None Ophthalmol. 1998;105(9):1715–20.

    CAS  Google Scholar 

  60. Parvizi S, Muthusamy K, Hingorani M, Dahlmann-Noor A. Topical ciclosporin 1 mg/ml for chronic ocular surface inflammation in children. Eye. 2018;32(7):1290–1.

    Article  Google Scholar 

  61. Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics. 2013;23(10):563.

    Article  CAS  Google Scholar 

  62. Yazu H, Shimizu E, Aketa N, Dogru M, Okada N, Fukagawa K, et al. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Ann Allergy Asthma Immunol. 2019;122(4):387–92.e1.

  63. Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol. 2014;157(2):280–6.

    Article  CAS  Google Scholar 

  64. García DP, Alperte JI, Cristóbal JA, Orobia AJM, Muro EM, Valyi Z, et al. Topical tacrolimus ointment for treatment of intractable atopic keratoconjunctivitis: a case report and review of the literature. Cornea. 2011;30(4):462–5.

    Article  Google Scholar 

  65. Stumpf T, Luqmani N, Sumich P, Cook S, Tole D. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25(10):1147–9.

    Article  Google Scholar 

  66. Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid–resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111(3):476–82.

  67. Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol. 2015;5(4):156–63.

    Article  Google Scholar 

  68. Taillé C, Doan S, Neukirch C, Aubier M. Omalizumab for severe atopic keratoconjunctivitis. BMJ Case Rep. 2010;2010:bcr0420102919.

  69. Fölster-Holst R, Torrelo A, Das K, Murrell DF, Patil A, Rahmat Pour Rokni G, et al. Biological medication in atopic dermatitis. Expert Opin Biol Ther. 2022;22(5):643–9.

  70. Chigbu DI, Labib BA. Immunopharmacology in vernal keratoconjunctivitis: current and future perspectives. Pharmaceuticals. 2021;14(7):658.

    Article  CAS  Google Scholar 

  71. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4s):S65-s76.

    Article  CAS  Google Scholar 

  72. Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-Induced Follicular Conjunctivitis. Ocul Immunol Inflamm. 2019;27(8):1339–41.

    Article  CAS  Google Scholar 

  73. Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegräber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatment. J Allergy Clin Immunol: In Practice. 2018;6(5):1778–80. e1.

  74. Chen J, Bielory L. Atopic Keratoconjunctivitis Alleviated With Dupilumab. Ann Allergy, Asthma Immunol. 2022.

  75. Fukuda K, Ebihara N, Kishimoto T, Fukushima A. Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis. J Allergy Clin Immunol In Practice. 2020;8(3):1152–5.

    Article  Google Scholar 

  76. Clark D, Cavanagh B, Shields AL, Karpecki P, Sheppard J, Brady TC. Clinically relevant activity of the novel rasp inhibitor reproxalap in allergic conjunctivitis: the Phase 3 ALLEVIATE trial. Am J Ophthalmol. 2021;230:60–7.

    Article  CAS  Google Scholar 

  77. Clinicaltrials.gov. Study evaluating the efficacy and safety of PRT-2761 for the treatment of acute and chronic allergic conjunctivitis. [July 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03320434. Accessed 1 Sept 2022.

Download references

Author information

Authors and Affiliations

  1. Massachusetts Eye and Ear Infirmary, Harvard Medical School, 1601 Trapelo Road Suite 184, Boston, MA, 02140, USA

    Sana Qureshi & Nandini Venkateswaran

Authors
  1. Sana Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nandini Venkateswaran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nandini Venkateswaran.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cornea

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qureshi, S., Venkateswaran, N. Atopic Keratoconjunctivitis: Diagnosis and Treatment. Curr Ophthalmol Rep 10, 130–137 (2022). https://doi.org/10.1007/s40135-022-00299-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40135-022-00299-z

Keywords

Search

Navigation